Trials / Completed
CompletedNCT00109161
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 270 (planned)
- Sponsor
- PDL BioPharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This research study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of daclizumab for the treatment of multiple sclerosis (MS).
Detailed description
PDL BioPharma, Inc. was formerly known as Protein Design Labs, Inc.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) |
Timeline
- Start date
- 2005-04-01
- Completion
- 2006-10-01
- First posted
- 2005-04-25
- Last updated
- 2008-08-05
Locations
36 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00109161. Inclusion in this directory is not an endorsement.